Advances in translational research have confirmed the biological and preclinical evidences making it increasingly apparent that BRCA1/2 mutations are biomarkers that may predict the clinical response of breast and ovarian cancer patients to platinum salts and poly (ADP-ribose) polymerase (PARP) inhibitors [6,7,8,9,10,11]. The gene discussed is BRCA1; the disease is ovarian cancer.